Titan Biotech (524717)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

Looking at Titan Biotech, I see a stock that has run from ₹88 to ₹577 in a year—a near seven-bagger. That alone makes me pause. But let's look beneath the surface. Sales grew 47.62% and profits 94.31%, with the latest quarter showing ₹57 Cr in sales and ₹9 Cr in net profit. That implies a net margin of roughly 15.8%, quite respectable for specialty chemicals. Return on equity is 17.92% and ROCE is 16.90%, both solid, suggesting management is deploying capital efficiently. The Piotroski F-score of 7/9 adds confidence in the underlying fundamentals. However, valuation is not cheap. At ₹576.80, the P/E stands at 36.73 and the price-to-book at 3.96. The PEG ratio of 0.52 suggests the market hasn't fully priced in the recent momentum, but that is a big 'if'. Growth at this pace is rarely sustainable; competition and base effects will inevitably slow things down. The dividend yield is negligible at 0.17%, so returns must come from earnings growth and continued re-rating. Debt-to-equity is not disclosed, which bothers me—I cannot fully assess balance sheet risk. Promoter holding is also unknown, leaving me without clarity on ownership alignment. I apply Ben Graham's margin of safety. At this price, I am paying a premium for quality and growth. The fundamentals are encouraging, but I would want more data on leverage, cash flow, and promoter backing before committing. A fast grower can be a wonderful business, but I must avoid overpaying for last year's numbers.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer